Vol. 20 Núm. 1 (2026): Revista Reumatología al Día
Reportes de Casos Clínicos

Paniculitis en dermatomiositis con positividad para anti-NXP2 y anti-Ro52. Reporte de caso

PDF
  • Goethe Salomón Sacoto Flores,
  • Karen Méndez Salvador,
  • Raúl Mejía Toalongo
Goethe Salomón Sacoto Flores
Universidad de Cuenca, Escuela de Medicina. Cuenca, Ecuador.
Karen Méndez Salvador
Universidad de Cuenca, Escuela de Medicina. Cuenca, Ecuador.
Raúl Mejía Toalongo
Universidad de Cuenca, Escuela de Medicina. Cuenca, Ecuador.
DOI: https://doi.org/10.62484/rad.v20i1.11718

Publicado 14-04-2026

Palabras clave

  • Dermatomiositis,
  • paniculitis,
  • anticuerpo anti-NXP2,
  • anticuerpo anti-Ro52,
  • calcinosis

Cómo citar

Sacoto Flores, G. S., Méndez Salvador, K., & Mejía Toalongo, R. (2026). Paniculitis en dermatomiositis con positividad para anti-NXP2 y anti-Ro52. Reporte de caso. Reumatología Al Día, 20(1), 6. https://doi.org/10.62484/rad.v20i1.11718

Derechos de autor 2026 Reumatología al Día

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.

Resumen

Las miopatías inflamatorias idiopáticas autoinmunes con positividad simultánea para anti-NXP2 y anti-Ro52 representan un subtipo infrecuente y de mal pronóstico; asociado a debilidad severa, paniculitis, calcinosis, mayor riesgo de cáncer asociado y riesgo de refractariedad. La paniculitis es una inflamación del tejido adiposo subcutáneo, caracterizada por nódulos dolorosos, eritematosos e indurados, que pueden evolucionar hacia lipoatrofia o calcificaciones. Aunque puede aparecer en el contexto de la fase inflamatoria activa de la dermatomiositis (DM), su frecuencia es baja. Se reporta una mujer de 39 años con dermatomiositis, paniculitis nodular-ulcerativa y calcinosis; con positividad para anti-NXP2 y anti-Ro52.

PDF

Métricas

Cargando métricas ...

Citas

  1. Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021 Dec 2;7(1):86. DOI: https://doi.org/10.1038/s41572-021-00321-x.
  2. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017 Dec;76(12):1955-64. DOI: https://doi.org/10.1136/annrheumdis-2017-211468
  3. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015 Apr 30;372(18):1734-47. DOI: https://doi.org/10.1056/NEJMra1402225.
  4. Krustev E, Christopher-Stine L. Autoantibodies in Myositis: Can They Predict Disease Course? Rheum Dis Clin North Am. 2025 Nov;51(4):545-62. DOI: https://doi.org/10.1016/j.rdc.2025.07.002.
  5. Aggarwal R, Oddis CV, editors. Managing Myositis: A Practical Guide [Internet]. Cham: Springer; 2020 [cited 2025 Jul 3]. DOI: https://doi.org/10.1007/978-3-030-15820-0.
  6. Kronzer VL, Kimbrough BA, Crowson CS, Davis JM, Holmqvist M, Ernste FC. Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study. Arthritis Care Res (Hoboken). 2023 Feb;75(2):348-55. DOI: https://doi.org/10.1002/acr.24786.
  7. Ho JD, McKenzie T. Panniculitis in dermatomyositis: a systematic review of the clinicopathologic features. JAAD Int. 2025 Feb;18:50-61. DOI: https://doi.org/10.1016/j.jdin.2024.03.004.
  8. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW. Measures for Adult and Juvenile Dermatomyositis, Polymyositis, and Inclusion Body Myositis. Arthritis Care Res (Hoboken). 2011;63 (Supl 11):S118–S157. DOI: https://doi.org/10.1002/acr.20532
  9. Takezawa K, Ueda-Hayakawa I, Tanaka A, Son Y, Yamazaki F, Kambe N, et al. Panniculitis in dermatomyositis: two cases with antitranscriptional intermediary factor-1 antibody as myositis-specific antibody and review of the literature. J Cutan Immunol Allergy. 2022;5:88-93. DOI: https://doi.org/10.1002/cia2.12234.
  10. Taguchi H, Ueda Y, Shigehara Y, Tanaka A, Katsuoka K. Relapse of dermatomyositis with positive anti-nuclear matrix protein 2 antibodies and previous panniculitis. Cureus. 2025 Feb 17;17(2):e78622. DOI: https://doi.org/10.7759/cureus.78622.
  11. Li S, Sun C, Zhang L, Han J, Yang H, Gao S, et al. Clinical heterogeneity of patients with antinuclear matrix protein 2 antibody-positive myositis: a retrospective cohort study in China. J Rheumatol. 2022 Jun 15;49(8):922-8. DOI: https://doi.org/10.3899/jrheum.211234.
  12. Sebastian AT, Sagar S, Mittal GK, Sebastian IA, Mateo JJ, Singhdev J, et al. A rare case of NXP-2 inflammatory myositis mimicking Guillain-Barré syndrome. Neurol India. 2023 May-Jun;71(3):582-4. DOI: https://doi.org/10.4103/0028-3886.378652.
  13. Xing XJ, Wang S, Li AQ, Li ZH, Lin BW. Panniculitis, a rare cutaneous manifestation in adult dermatomyositis. Int J Dermatol Venereol. 2023 Jun;6(2):96-101. DOI: https://doi.org/10.1097/JD9.0000000000000260.
  14. Sugita T, Tsuboi H, Sugita N, Akiyoshi R, Kuroda Y, Kawashima A, et al. Clinical importance of anti-Ro52 antibody in polymyositis and dermatomyositis. Mod Rheumatol. 2024 Dec 25;35(1):118-25. DOI: https://doi.org/10.1093/mr/roae052.
  15. Weng CT, Huang TH, Wu CH, Sun YT. Association of anti-Ro-52 antibodies with occurrence of interstitial lung disease in patients with idiopathic inflammatory myopathy. Arthritis Res Ther. 2024 Aug 22;26(1):152. DOI: https://doi.org/10.1186/s13075-024-03382-x.
  16. Xing X, Li A, Li C. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respir Med. 2020 Oct;172:106134. DOI: https://doi.org/10.1016/j.rmed.2020.106134.
  17. Arase N, Tsuji H, Takamatsu H, Jin H, Konaka H, Hamaguchi Y, et al. Cell surface-expressed Ro52/IgG/HLA-DR complex is targeted by autoantibodies in patients with inflammatory myopathies. J Autoimmun. 2022 Jan;126:102774. DOI: https://doi.org/10.1016/j.jaut.2021.102774.
  18. Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, et al. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2019 Jul;78(7):988-95. DOI: https://doi.org/10.1136/annrheumdis-2018-215004.
  19. Ismail A, Moiddin NM, Mahmood MA, Khan AU, Nagaraj N. Anti-Ro-positive dermatomyositis presenting as a clinical mimic of Guillain-Barré syndrome: a case report. Cureus. 2024. DOI: https://doi.org/10.7759/cureus.73410.